Heparin-Induced Thrombocytopenia: A Comprehensive Clinical Review

Journal of the American College of Cardiology

Volumn 67, Issue 21, 2016, Pages 2519-2532

  Salter, Benjamin S ^a   Weiner, Menachem M ^a   Trinh, Muoi A ^a   Heller, Joshua ^a   Evans, Adam S ^a   Adams, David H ^a   Fischer, Gregory W ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

anticoagulant agents; antithrombin agents; argatroban; bivalirudin; cardiopulmonary bypass; platelets

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; FONDAPARINUX; HEPARIN; HIRULOG; ANTITHROMBIN; BIVALIRUDIN; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; PIPECOLIC ACID DERIVATIVE; POLYSACCHARIDE; RECOMBINANT PROTEIN;

CARDIOPULMONARY BYPASS; CATHETERIZATION; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DIAGNOSTIC ERROR; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INCIDENCE; LABORATORY TEST; MOLECULAR PATHOLOGY; MORBIDITY; MORTALITY; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; BLOOD CLOTTING PARAMETERS; CHEMICALLY INDUCED; PERCUTANEOUS CORONARY INTERVENTION;

ANTICOAGULANTS; ANTITHROMBINS; CARDIOPULMONARY BYPASS; HEPARIN; HIRUDINS; HUMANS; INCIDENCE; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; PIPECOLIC ACIDS; PLASMAPHERESIS; PLATELET FUNCTION TESTS; PLATELET TRANSFUSION; POLYSACCHARIDES; RECOMBINANT PROTEINS; RISK FACTORS; THROMBOCYTOPENIA;

EID: 84969962283     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.02.073     Document Type: Review

References (170)

1. R. Dasararaju, N. Singh, and A. Mehta Heparin-induced thrombocytopenia: review Expert Rev Hematol 6 2013 419 428
2. I.K. Jang, and M.J. Hursting When heparins promote thrombosis: review of heparin-induced thrombocytopenia Circulation 111 2005 2671 2683
3. S. Battistelli, A. Genovese, and T. Gori Heparin-induced thrombocytopenia in surgical patients Am J Surg 199 2010 43 51
4. T.E. Warkentin, and A. Greinacher Heparin-induced thrombocytopenia and cardiac surgery Ann Thorac Surg 76 2003 2121 2131
5. I. Ahmed, A. Majeed, and R. Powell Heparin-induced thrombocytopenia: diagnosis and management update Postgrad Med J 83 2007 575 582
6. L.A. Linkins, A.L. Dans, L.K. Moores, and et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines Chest 141 2012 e495S e530S
7. G.M. Arepally, and T.L. Ortel Clinical practice. Heparin-induced thrombocytopenia N Engl J Med 355 2006 809 817
8. F. Lovecchio Heparin-induced thrombocytopenia Clin Toxicol (Phila) 52 2014 579 583
9. J.W. Szokol Heparin-induced thrombocytopenia Semin Cardiothorac Vasc Anesth 14 2010 73 74
10. T.E. Warkentin, A. Greinacher, A. Koster, and et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition) Chest 133 2008 340S 380S
11. S. Lanzarotti, and J.A. Weigelt Heparin-induced thrombocytopenia Surg Clin North Am 92 2012 1559 1572
12. B.H. Chong Heparin-induced thrombocytopenia J Thromb Haemost 1 2003 1471 1478
13. T.E. Warkentin An overview of the heparin-induced thrombocytopenia syndrome Semin Thromb Hemost 30 2004 273 283
14. K.J. Grubb, P. Salehi, and E.G. Chedrawy Bivalirudin: alternative anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia Recent Pat Cardiovasc Drug Discov 5 2010 20 24
15. S.X. Anand, J.F. Viles-Gonzalez, S.K. Mahboobi, and et al. Bivalirudin utilization in cardiac surgery: shifting anticoagulation from indirect to direct thrombin inhibition Can J Anesth 58 2010 296 311
16. L.A. Linkins Heparin induced thrombocytopenia BMJ 350 2015 g7566
17. B.S. Sachais, A.H. Rux, D.B. Cines, and et al. Rational design and characterization of platelet factor 4 antagonists for the study of heparin-induced thrombocytopenia Blood 119 2012 5955 5962
18. J.M. Walenga, W.P. Jeske, and H.L. Messmore Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia J Thromb Thrombolysis 10 Suppl 1 2000 13 20
19. A. Cuker, and D.B. Cines How I treat heparin-induced thrombocytopenia Blood 119 2012 2209 2218
20. E.M. Crespo, G.B.F. Oliveira, E.F. Honeycutt, et al. for the CATCH Registry Investigators Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: the Complications After Thrombocytopenia Caused by Heparin (CATCH) registry Am Heart J 157 2009 651 657
21. S. Kato, K. Takahashi, K. Ayabe, and et al. Heparin-induced thrombocytopenia: analysis of risk factors in medical inpatients Br J Haematol 154 2011 373 377
22. N. Martel, J. Lee, and P.S. Wells Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis Blood 106 2005 2710 2715
23. T.E. Warkentin, M.N. Levine, J. Hirsh, and et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin N Engl J Med 332 1995 1330 1335
24. G.M. Arepally, and T.L. Ortel Heparin-induced thrombocytopenia Annu Rev Med 61 2010 77 90
25. G.P. Visentin, M. Malik, K.A. Cyganiak, and et al. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes J Lab Clin Med 128 1996 376 383
26. P. Prandoni, S. Siragusa, B. Girolami, et al. for the BELZONI Investigators Group The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study Blood 106 2005 3049 3054
27. T.E. Warkentin, R.J. Cook, V.J. Marder, and et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin Blood 106 2005 3791 3796
28. T.E. Warkentin Fondaparinux: does it cause HIT? Can it treat HIT? Expert Rev Hematol 3 2010 567 581
29. J.L. Francis, G.J. Palmer III, R. Moroose, and et al. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery Ann Thorac Surg 75 2003 17 22
30. A.A. Muslimani, B. Ricaurte, and H.A. Daw Immune heparin-induced thrombocytopenia resulting from preceding exposure to heparin catheter flushes Am J Hematol 82 2007 652 655
31. K. Selleng, T.E. Warkentin, and A. Greinacher Heparin-induced thrombocytopenia in intensive care patients Crit Care Med 35 2007 1165 1176
32. T.E. Warkentin Heparin-induced thrombocytopenia in critically ill patients Crit Care Clin 27 2011 805 823
33. T.E. Warkentin, J.A. Sheppard, P. Horsewood, and et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia Blood 96 2000 1703 1708
34. T.E. Warkentin, J.A.I. Sheppard, C.S. Sigouin, and et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia Blood 108 2006 2937 2941
35. T.E. Warkentin, and J.G. Kelton Temporal aspects of heparin-induced thrombocytopenia N Engl J Med 344 2001 1286 1292
36. A. Cuker, G. Arepally, M.A. Crowther, and et al. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion J Thromb Haemost 8 2010 2642 2650
37. C. Pouplard, M.A. May, S. Regina, and et al. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies Br J Haematol 128 2005 837 841
38. G.A. Nuttall, W.C. Oliver Jr., P.J. Santrach, and et al. Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series Anesth Analg 96 2003 344 350
39. A. Lillo-Le Louët, P. Boutouyrie, M. Alhenc-Gelas, and et al. Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass J Thromb Haemost 2 2004 1882 1888
40. E. Shantsila, G.Y.H. Lip, and B.H. Chong Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management Chest 135 2009 1651 1664
41. G.M. Lee, and G.M. Arepally Heparin-induced thrombocytopenia Hematology Am Soc Hematol Educ Program 2013 2013 668 674
42. A. Koster, C.M. Dyke, G. Aldea, and et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial Ann Thorac Surg 83 2007 572 577
43. T.E. Warkentin Heparin-induced thrombocytopenia in critically ill patients Semin Thromb Hemost 41 2015 49 60
44. T.E. Warkentin Heparin-induced thrombocytopenia: pathogenesis and management Br J Haematol 121 2003 535 555
45. G.K. Lo, D. Juhl, T.E. Warkentin, and et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings J Thromb Haemost 4 2006 759 765
46. T.E. Warkentin, R.S. Roberts, J. Hirsh, and et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients Arch Intern Med 163 2003 2518 2524
47. A. Cuker, P.A. Gimotty, M.A. Crowther, and et al. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis Blood 120 2012 4160 4167
48. A. Greinacher Clinical practice. Heparin-induced thrombocytopenia N Engl J Med 373 2015 252 261
49. S.E. McKenzie, and B.S. Sachais Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia Curr Opin Hematol 21 2014 380 387
50. T.E. Warkentin, J.A.I. Sheppard, J.C. Moore, and et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 146 2005 341 346
51. D. Juhl, P. Eichler, N. Lubenow, and et al. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia Eur J Haematol 76 2006 420 426
52. R.F. Reilly The pathophysiology of immune-mediated heparin-induced thrombocytopenia Semin Dial 16 2003 54 60
53. M.B. Zucker, and I.R. Katz Platelet factor 4: production, structure, and physiologic and immunologic action Proc Exp Biol Med 198 1991 693 702
54. M.M. Prechel, and J.M. Walenga Emphasis on the role of PF4 in the incidence, pathophysiology and treatment of heparin-induced thrombocytopenia Thromb J 11 2013 7
55. A. Greinacher, D. Juhl, U. Strobel, and et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes J Thromb Haemost 5 2007 1666 1673
56. S. Selleng, B. Malowsky, T. Itterman, and et al. Incidence and clinical relevance of anti-platelet factor 4/heparin antibodies before cardiac surgery Am Heart J 160 2010 362 369
57. V. Regnault, E. de Maistre, J.P. Carteaux, and et al. Platelet activation induced by human antibodies to interleukin-8 Blood 101 2002 1419 1421
58. C. Pouplard, D. Leroux, S. Regina, and et al. Effectiveness of a new immunoassay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies Thromb Haemost 103 2010 145 150
59. E. Lindhoff-Last, F. Gerdsen, H. Ackermann, and et al. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia Br J Haematol 113 2001 886 890
60. T.E. Warkentin, and J.A.I. Sheppard Testing for heparin-induced thrombocytopenia antibodies Transfus Med Rev 20 2006 259 272
61. J.H. Levy, and A.M. Winkler Heparin-induced thrombocytopenia and cardiac surgery Curr Opin Anaesthesiol 23 2010 74 79
62. T. Bakchoul, A. Giptner, A. Najaoui, and et al. Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia J Thromb Haemost 7 2009 1260 1265
63. T.E. Warkentin, J.I. Sheppard, J.C. Moore, and et al. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays J Thromb Haemost 6 2008 1304 1312
64. A. Greinacher, T. Ittermann, J. Bagemühl, and et al. Heparin-induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests J Thromb Haemost 8 2010 2025 2031
65. J.I. Zwicker, L. Uhl, W.Y. Huang, and et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia J Thromb Haemost 2 2004 2133 2137
66. F. Altuntas, K. Matevosyan, J. Burner, and et al. Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia Eur J Haematol 80 2008 429 435
67. S. Baroletti, S. Hurwitz, N.A.S. Conti, and et al. Thrombosis in suspected heparin-induced thrombocytopenia occurs more often with high antibody levels Am J Med 125 2012 44 49
68. C.M. Chan, C.J. Woods, T.E. Warkentin, and et al. The role for optical density in heparin-induced thrombocytopenia: a cohort study Chest 148 2015 55 61
69. N.L. Whitlatch, D.F. Kong, A.D. Metjian, and et al. Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia Blood 116 2010 1761 1766
70. J. McFarland, A. Lochowicz, R. Aster, and et al. Improving the specificity of the PF4 ELISA in diagnosing heparin-induced thrombocytopenia Am J Hematol 87 2012 776 781
71. T. Bakchoul, A. Giptner, G. Bein, and et al. Performance characteristics of two commercially available IgG-specific immunoassays in the assessment of heparin-induced thrombocytopenia (HIT) Thromb Res 127 2011 345 348
72. T.E. Warkentin Platelet microparticle generation assay for detection of HIT antibodies: advance, retreat, or too soon to tell? Thromb Res 133 2014 957 958
73. T.E. Warkentin, D.M. Arnold, I. Nazi, and et al. The platelet serotonin-release assay Am J Hematol 90 2015 564 572
74. T. Bakchoul, H. Zöllner, and A. Greinacher Current insights into the laboratory diagnosis of HIT Int J Lab Hematol 36 2014 296 305
75. D. Sheridan, C. Carter, and J.G. Kelton A diagnostic test for heparin-induced thrombocytopenia Blood 67 1986 27 30
76. F. Mullier, V. Minet, N. Bailly, and et al. Platelet microparticle generation assay: a valuable test for immune heparin-induced thrombocytopenia diagnosis Thromb Res 133 2014 1068 1073
77. B. Cosmi Current management of heparin-induced thrombocytopenia Expert Rev Hematol 8 2015 837 849
78. T.E. Warkentin Heparin-induced thrombocytopenia Hematol Oncol Clin North Am 21 2007 589 607
79. T.E. Warkentin, B.T. Maurer, and R.H. Aster Heparin-induced thrombocytopenia associated with fondaparinux N Engl J Med 356 2007 2653 2655
80. E. Rota, M. Bazzan, and G. Fantino Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT) Thromb Haemost 99 2008 779 781
81. M. Salem, S. Elrefai, M.A. Shrit, and et al. Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke Thromb Haemost 104 2010 1071 1072
82. V.R. Bhatt, M.R. Aryal, R. Shrestha, and et al. Fondaparinux-associated heparin-induced thrombocytopenia Eur J Haematol 91 2013 437 441
83. T.E. Warkentin, and J.G. Kelton A 14-year study of heparin-induced thrombocytopenia Am J Med 101 1996 502 507
84. D.E. Wallis, D.L. Workman, B.E. Lewis, and et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia Am J Med 106 1999 629 635
85. B.E. Lewis, D.E. Wallis, F. Leya, et al. for the Argatroban-915 Investigators Argatroban anticoagulation in patients with heparin-induced thrombocytopenia Arch Intern Med 163 2003 1849
86. R.B. Babcock, C.W. Dumper, and W.B. Scharfman Heparin-induced immune thrombocytopenia N Engl J Med 295 1976 237 241
87. P.L. Cimo, J.L. Moake, R.S. Weinger, and et al. Heparin-induced thrombocytopenia: association with a platelet aggregating factor and arterial hrombosis Am J Hematol 6 1979 125 133
88. M.A. Refaai, C. Chuang, M. Menegus, and et al. Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia J Thromb Haemost 8 2010 1419 1421
89. C.K. Hopkins, and D. Goldfinger Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature Transfusion 48 2008 2128 2132
90. R. Goel, P.M. Ness, C.M. Takemoto, and et al. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality Blood 125 2015 1470 1476
91. T.E. Warkentin Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls Expert Opin Drug Saf 13 2014 25 43
92. J.G. Kelton, D.M. Arnold, and S.M. Bates Nonheparin anticoagulants for heparin-induced thrombocytopenia N Engl J Med 368 2013 737 744
93. D. Rund, and E. Rachmilewitz Advances in the pathophysiology and treatment of thalassemia Crit Rev Oncol Hematol 20 1995 237 254
94. A. Greinacher, H. Völpel, U. Janssens, and et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study Circulation 99 1999 73 80
95. L.P. Skrupky, J.R. Smith, E.N. Deal, and et al. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia Pharmacotherapy 30 2010 1229 1238
96. T.H. Kiser, J.C. Burch, P.M. Klem, and et al. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia Pharmacotherapy 28 2008 1115 1124
97. C.H. Dang, V.L. Durkalski, and J.M. Nappi Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia Pharmacotherapy 26 2006 461 468
98. C.M. Vun, S. Evans, and B.H. Chong Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopenia Thromb Res 81 1996 525 532
99. P.M. Newman, R.L. Swanson, and B.H. Chong Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid Thromb Haemost 80 1998 292 297
100. Argatroban injection: highlights of prescribing information 2016 GlaxoSmithKline Research Triangle Park, North Carolina Available at https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing-Information/Argatroban/pdf/ARGATROBAN.PDF Accessed March 24, 2016
101. C.J. Lee, and J.E. Ansell Direct thrombin inhibitors Br J Clin Pharmacol 72 2011 581 592
102. E.A. Nutescu, N.L. Shapiro, and A. Chevalier New anticoagulant agents: direct thrombin inhibitors Cardiol Clin 26 2008 169 187
103. Argatroban-argatroban injection, solution 2009 GlaxoSmithKline Research Triangle Park, NC Available at http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/pediatricadvisorycommittee/ucm192057.pdf Accessed March 24, 2016
104. S.K. Swan, and M.J. Hursting The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction Pharmacotherapy 20 2000 318 329
105. B.E. Lewis, W.H. Matthai Jr., M. Cohen, et al. for the ARB-216/310/311 Study Investigators Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia Catheter Cardiovasc Interv 57 2002 177 184
106. S.X. Anand, M.C. Kim, M. Kamran, and et al. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin Am J Cardiol 100 2007 417 424
107. Q.A. Vo, J.K. Lin, and L.M. Tong Efficacy and safety of argatroban and bivalirudin in patients with suspected heparin-induced thrombocytopenia Ann Pharmacother 49 2014 178 184
108. J. Bain, and A. Meyer Comparison of bivalirudin to lepirudin and argatroban in patients with heparin-induced thrombocytopenia Am J Health Syst Pharm 72 2015 S104 S109
109. L. Joseph, A.I. Casanegra, M. Dhariwal, and et al. Bivalirudin for the treatment of patients with confirmed or suspected heparin-induced thrombocytopenia J Thromb Haemost 12 2014 1044 1053
110. T.E. Warkentin, and A. Koster Bivalirudin: a review Expert Opin Pharmacother 6 2005 1349 1371
111. Angiomax: prescribing information 2016 The Medicines Company Parsippany, New Jersey Available at http://www.angiomax.com/downloads/ANG-USPI.pdf Accessed March 24, 2016
112. R. Robson, H. White, P. Aylward, and et al. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender Clin Pharmacol Ther 71 2002 433 439
113. R.M. Lidon, P. Théroux, M. Juneau, and et al. Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects Circulation 88 1993 1495 1501
114. I. Fox, A. Dawson, P. Loynds, and et al. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans Thromb Haemost 69 1993 157 163
115. G. Nowak The ecarin clotting time, a universal method to quantify direct thrombin inhibitors Pathophysiol Haemost Thromb 33 2003 173 183
116. L.V. Tsu, and W.E. Dager Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia Ann Pharmacother 45 2011 1185 1192
117. T.H. Kiser, and D.N. Fish Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction Pharmacotherapy 26 2006 452 460
118. Arixtra (fondaparinux sodium) injection 2005 GlaxoSmithKline Research Triangle Park, NC Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2005/021345s010lbl.pdf Accessed March 24, 2015
119. F. Donat, J.P. Duret, A. Santoni, and et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers Clin Pharmacokinet 41 Suppl 2 2002 1 9
120. P. Savi, B.H. Chong, A. Greinacher, and et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin Blood 105 2005 139 144
121. E. Grouzi, E. Kyriakou, I. Panagou, and et al. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience Clin Appl Thromb Hemost 16 2010 663 667
122. B. Lobo, C. Finch, A. Howard, and et al. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia Thromb Haemost 99 2008 208 214
123. M. Kang, M. Alahmadi, S. Sawh, and et al. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study Blood 125 2015 924 929
124. J.S. Vender, E.B. Matthew, I.M. Silverman, and et al. Heparin-associated thrombocytopenia: alternative managements Anesth Analg 65 1986 520 522
125. S. Nand, and J.A. Robinson Plasmapheresis in the management of heparin-associated thrombocytopenia with thrombosis Am J Hematol 28 1988 204 206
126. J.L. Bouvier, P. Lefevre, P. Villain, and et al. Treatment of serious heparin-induced thrombocytopenia by plasma exchange: report on 4 cases Thromb Res 51 1988 335 336
127. M. Kajitani, M. Aguinaga, C.E. Johnson, and et al. Use of plasma exchange and heparin during cardiopulmonary bypass for a patient with heparin-induced thrombocytopenia: a case report J Card Surg 16 2001 313 318
128. I.J. Welsby, J. Um, C.A. Milano, and et al. Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia Anesth Analg 110 2010 30 35
129. D. Thorp, A. Canty, J. Whiting, and et al. Plasma exchange and heparin-induced thrombocytopenia Prog Clin Biol Res 337 1990 521 522
130. E.A. Jaben, A.S. Torloni, R.K. Pruthi, and et al. Use of plasma exchange in patients with heparin-induced thrombocytopenia: a report of two cases and a review of the literature J Clin Apher 26 2011 219 224
131. R.K. Voeller, S.J. Melby, B.E. Grizzell, and et al. Novel use of plasmapheresis in a patient with heparin-induced thrombocytopenia requiring urgent insertion of a left ventricular assist device under cardiopulmonary bypass J Thorac Cardiovasc Surg 140 2010 e56 e58
132. J. Brady, J.A. Riccio, O.H. Yumen, and et al. Plasmapheresis. A therapeutic option in the management of heparin-associated thrombocytopenia with thrombosis Am J Clin Pathol 96 1991 394 397
133. P. Poullin, P.A. Pietri, and P. Lefèvre Heparin-induced thrombocytopenia with thrombosis: successful treatment with plasma exchange Br J Haematol 102 1998 630 631
134. H.N. Abdel-Razeq, A.A. Bajouda, and et al. Treating heparin-induced thrombocytopenia. The unconventional way! Saudi Med J 25 2004 1258 1260
135. N.M. Antonijevic, N.B. Savic, J. Perunicic, and et al. Salvage late plasmapheresis in a patient with pulmonary embolism caused by heparin-induced thrombocytopenia primarily resistant to danaparoid sodium and lepirudin J Clin Apher 21 2006 252 255
136. R. Kramer, P. Oberg-Higgins, L. Russo, and et al. Heparin-induced thrombocytopenia with thrombosis syndrome managed with plasmapheresis Interact Cardiovasc Thorac Surg 8 2009 439 441
137. J.A. Robinson, and B.E. Lewis Plasmapheresis in the management of heparin-induced thrombocytopenia Semin Hematol 36 1999 29 32
138. J. Schwartz, J.L. Winters, A. Padmanabhan, and et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue J Clin Apher 28 2013 145 284
139. E. Iluonakhamhe, O. Ibekwe, S. Samuel, and et al. Plasmapheresis may be an option in urgent management of heparin-induced thrombocytopenia in the setting of acute intracerebral hemorrhage Neurocrit Care 22 2015 140 145
140. D.E. Wallis, R. Quintos, W. Wehrmacher, and et al. Safety of warfarin anticoagulation in patients with heparin-induced thrombocytopenia Chest 116 1999 1333 1338
141. T.E. Warkentin HITlights: a career perspective on heparin-induced thrombocytopenia Am J Hematol 87 Suppl 1 2012 S92 S99
142. Cuker A, Crowther MA. 2013 clinical practice guideline on the evaluation and management of adults with suspected heparin-induced thrombocytopenia. Available at: http://www.hematology.org/Clinicians/Guidelines-Quality/Quick-Ref/529.aspx. Accessed March 24, 2015.
143. F. Follis, G. Filippone, G. Montalbano, and et al. Argatroban as a substitute of heparin during cardiopulmonary bypass: a safe alternative? Interact Cardiovasc Thorac Surg 10 2010 592 596
144. T.E. Warkentin HIT paradigms and paradoxes J Thromb Haemost 9 Suppl 1 2011 105 117
145. S. Selleng, N. Lubenow, H.G. Wollert, and et al. Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: successful reexposure to heparin Ann Thorac Surg 71 2001 1041 1042
146. B. Pötzsch, W.P. Klövekorn, and K. Madlener Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia N Engl J Med 343 2000 515
147. N. Lubenow, R. Kempf, A. Eichner, and et al. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin Chest 122 2002 37 42
148. K.B. Leissner, A. Ketchedjian, R. Crowley, and et al. Deep hypothermic circulatory arrest and bivalirudin use in a patient with heparin-induced thrombocytopenia and antiphospholipid syndrome J Card Surg 22 2007 78 82
149. M.E. Martin, G.H. Kloecker, and D.A. Laber Argatroban for anticoagulation during cardiac surgery Eur J Haematol 78 2006 161 166
150. V.P. Addonizio Jr., C.A. Fisher, J.R. Kappa, and et al. Prevention of heparin-induced thrombocytopenia during open heart surgery with iloprost (ZK36374) Surgery 102 1987 796 807
151. A. Aouifi, P. Blanc, V. Piriou, and et al. Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia Ann Thorac Surg 71 2001 678 683
152. F. Mertzlufft, H. Kuppe, and A. Koster Management of urgent high-risk cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and coexisting disorders of renal function: use of heparin and epoprostenol combined with on-line monitoring of platelet function J Cardiothorac Vasc Anesth 14 2000 304 308
153. A. Greinacher The use of direct thrombin inhibitors in cardiovascular surgery in patients with heparin-induced thrombocytopenia Semin Thromb Hemost 30 2004 315 327
154. A.F. Merry, P.J. Raudkivi, N.G. Middleton, and et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery Ann Thorac Surg 77 2004 925 931 discussion 931
155. C.M. Dyke, G. Aldea, A. Koster, and et al. Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies Ann Thorac Surg 84 2007 836 839
156. C.M. Dyke, N.G. Smedira, A. Koster, and et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study J Thorac Cardiovasc Surg 131 2006 533 539
157. N.G. Smedira, C.M. Dyke, A. Koster, and et al. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study J Thorac Cardiovasc Surg 131 2006 686 692
158. G.S. Murphy, and J.H. Marymont Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery J Cardiothorac Vasc Anesth 21 2007 113 126
159. C.M. Dyke, A. Koster, J.J. Veale, and et al. Preemptive use of bivalirudin for urgent on-pump coronary artery bypass grafting in patients with potential heparin-induced thrombocytopenia Ann Thorac Surg 80 2005 299 303
160. A. Koster, S. Buz, T. Krabatsch, and et al. Effect of modified ultrafiltration on bivalirudin elimination and postoperative blood loss after on-pump coronary artery bypass grafting: assessment of different filtration strategies J Card Surg 23 2008 655 658
161. J.K. Wong, Y. Tian, P. Shuttleworth, and et al. Case report: a thrombus in the venous reservoir while using bivalirudin in a patient with heparin-induced thrombocytopenia undergoing heart transplantation Anesth Analg 111 2010 609 612
162. J.A. Bittl, J. Strony, J.A. Brinker, et al. for the Hirulog Angioplasty Study Investigators Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina N Engl J Med 333 1995 764 769
163. J.A. Bittl, F. Feit for the Hirulog Angioplasty Study Investigators A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina Am J Cardiol 82 Suppl 1998 43P 49P
164. H.S. Gurm, and D.L. Bhatt Thrombin, an ideal target for pharmacological inhibition: a review of direct thrombin inhibitors Am Heart J 149 2005 S43 S53
165. A.M. Lincoff, J.A. Bittl, N.S. Kleiman, et al. for the REPLACE-1 Investigators Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial) Am J Cardiol 93 2004 1092 1096
166. A.M. Lincoff, J.A. Bittl, R.A. Harrington, et al. for the REPLACE-2 Investigators Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial JAMA 289 2003 853 863
167. M.S. Lee, H. Liao, T. Yang, and et al. Comparison of bivalirudin versus heparin plus glycoprotein Iib/IIIa inhibitors in patients undergoing an invasive strategy: a meta-analysis of randomized clinical trials Int J Cardiol 152 2011 369 374
168. A. Shahzad, I. Kemp, C. Mars, et al. for the HEAT-PPCI Trial Investigators Unfractionated Heparin versus Bivalirudin in Primary Percutaneous Coronary Intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial Lancet 384 2014 1849 1858
169. P.G. Steg, A. van 't Hof, C.W. Hamm, et al. for the EUROMAX Investigators Bivalirudin started during emergency transport for primary PCI N Engl J Med 369 2013 2207 2217
170. G.W. Stone, B. Witzenbichler, G. Guagliumi, et al. for the HORIZONS-AMI Trial Investigators Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2008 2218 2230